$266.900
-4.084 (-1.53%)At close
IQV News
IQV Events
IQVIA and Veeva Expand Partnership
IQVIA (IQV) and Veeva Systems (VEEV) announced an expansion of their partnership with the selection of Veeva CTMS, eTMF, Study Startup, and Site Connect as enterprise standard applications that will be used across IQVIA clinical development studies. This extends the previously announced EDC partnership. "This is an exciting expansion of the partnership IQVIA and Veeva announced last year and the work we have done together since," said Veeva founder and CEO Peter Gassner. "We are committed to supporting seamless product and services integration for the benefit of our customers and improving access to innovations for patients."
Iqvia Launches Life Science Models to Predict Clinical Trial Outcomes
Iqvia (IQV) introduced Iqvia Life Science Models to help predict clinical trial outcomes. Iqvia Life Science Models are a suite of purpose-built models for life sciences, combining Iqvia's proprietary expert content, deep domain knowledge and established regulatory, compliance and privacy frameworks. Built using technologies including Nvidia (NVDA) Nemotron and supported by Amazon Web Services (AMZN) infrastructure, the models connect molecular and treatment information with patient journeys and clinical outcomes to enable predictive applications across clinical development.
Iqvia Launches Iqvia Explorer to Enhance Commercial Decision-Making
Iqvia introduced Iqvia Explorer to help customers make better-informed commercial decisions. Iqvia Explorer turns complex, one-time analytics projects into an always-on commercial intelligence capability. Users can apply external indicators and ask business questions, and Explorer brings together the relevant Iqvia data, analytical methods and workflows to provide near real-time intelligence to support decision-making. This allows teams to identify opportunities sooner, improve execution and make faster, more informed decisions that drive commercial performance and ROI. "In a market defined by complexity, volatility and margin compression, improving productivity requires commercial teams to respond faster to change, execute more efficiently and deliver stronger business outcomes," said Pete Groves, EVP, AI & Technology Solutions at Iqvia. "Our customers trust IQVIA's data foundation and advanced analytical capabilities to understand performance today and model what may happen tomorrow. IQVIA Explorer does both, in a matter of minutes."
The Trade Desk Expands Integrations with Veeva and IQVIA
The Trade Desk announced expanded integrations with healthcare analytics and measurement providers Veeva Crossix and IQVIA Digital. The enhancements give pharma advertisers more granular insights into campaign performance and new ways to apply those insights to media optimization and decisioning. Pharma analytics has traditionally focused on evaluating campaign effectiveness and identifying optimization opportunities outside the platform environment. The Trade Desk is helping shrink the gap between insight and action by bringing more healthcare data, greater choice and more granular measurement and optimization closer to media decisioning, giving advertisers the ability to apply learnings and make optimizations while campaigns are still running.
IQVIA Plans to Raise $2 Billion Through Senior Notes Offering
IQVIA Holdings announced that its wholly owned subsidiary, IQVIA, intends to raise $2,000,000,000 through an offering of senior notes due 2034. The proceeds from the Notes offering will be used to redeem in full the Issuer's Senior 5.000% Notes due 2026, to repay a portion of the outstanding indebtedness under the Issuer's revolving credit facility and to pay fees and expenses related to the Notes offering. The consummation of the Notes offering is subject to market and other customary conditions.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.